Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs.

Veterinary Therapeutics Pub Date : 2008-01-01

Linda L Black, James Gaynor, Cheryl Adams, Sarit Dhupa, Andrew E Sams, Robert Taylor, Susan Harman, Daniel A Gingerich, Robert Harman

{"title":"Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs.","authors":"Linda L Black, James Gaynor, Cheryl Adams, Sarit Dhupa, Andrew E Sams, Robert Taylor, Susan Harman, Daniel A Gingerich, Robert Harman","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Autologous adipose-derived mesenchymal stem cell (AD-MSC) therapy involves harvesting fat from the patient, isolating the stem and regenerative cells, and administering the cells back to the patient. Autologous AD-MSC therapy in veterinary regenerative medicine has been commercially available since 2003. Previously reported results from a blinded, controlled trial in dogs with chronic osteoarthritis of the coxofemoral (hip) joint demonstrated efficacy of a single intraarticular injection of autologous AD-MSC therapy. The primary objective of the current study was to evaluate the effectiveness of this therapy in dogs with chronic osteoarthritis of the humeroradial (elbow) joints and to determine the duration of effect. Fourteen dogs were recruited. Veterinarians assessed each dog for lameness, pain on manipulation, range of motion, and functional disability using a numeric rating scale at baseline and specified intervals up to 180 days after treatment. Statistically significant improvement in outcome measures was demonstrated.</p>","PeriodicalId":51211,"journal":{"name":"Veterinary Therapeutics","volume":"9 3","pages":"192-200"},"PeriodicalIF":0.0000,"publicationDate":"2008-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary Therapeutics","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Autologous adipose-derived mesenchymal stem cell (AD-MSC) therapy involves harvesting fat from the patient, isolating the stem and regenerative cells, and administering the cells back to the patient. Autologous AD-MSC therapy in veterinary regenerative medicine has been commercially available since 2003. Previously reported results from a blinded, controlled trial in dogs with chronic osteoarthritis of the coxofemoral (hip) joint demonstrated efficacy of a single intraarticular injection of autologous AD-MSC therapy. The primary objective of the current study was to evaluate the effectiveness of this therapy in dogs with chronic osteoarthritis of the humeroradial (elbow) joints and to determine the duration of effect. Fourteen dogs were recruited. Veterinarians assessed each dog for lameness, pain on manipulation, range of motion, and functional disability using a numeric rating scale at baseline and specified intervals up to 180 days after treatment. Statistically significant improvement in outcome measures was demonstrated.

本刊更多论文

关节内注射自体脂肪源性间充质干细胞和再生细胞对犬肘关节慢性骨关节炎临床症状的影响。

自体脂肪源性间充质干细胞(AD-MSC)治疗包括从患者身上收集脂肪，分离干细胞和再生细胞，并将细胞送回患者体内。自2003年以来，动物再生医学中的自体AD-MSC治疗已经商业化。先前报道的一项盲法、对照试验结果表明，单次关节内注射自体AD-MSC治疗对患有髋部慢性骨关节炎的狗有效。本研究的主要目的是评估这种疗法对患有肱骨(肘关节)慢性骨关节炎的狗的有效性，并确定效果的持续时间。招募了14只狗。兽医对每只狗的跛行、操作疼痛、活动范围和功能残疾进行评估，在基线和治疗后180天的指定间隔使用数字评定量表。结果指标有统计学上的显著改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Veterinary Therapeutics

自引率

0.00%

发文量